Versartis, a biopharmaceutical company, announced the promotion of Joshua T. Brumm to chief operating officer and Paul Westberg to chief business officer.
Versartis appoints two executivesStaff Writer | Menlo Park, Ca., USA | Wednesday February 1, 2017 4:33AM ET
READ MOREMr. Brumm has more than a decade of operations, corporate finance and investment banking experience in the life science industry.
Mr. Brumm was named Silicon Valley Business Journal's CFO of the Year for companies under $500 million in 2014 and finalist for the Bay Area CFO of the Year Awards in the small public company category during 2016.
Prior to Versartis, Mr. Brumm served as Executive Vice President of Finance and Principal Financial Officer for Pharmacyclics Inc.
Previously he held the role of Chief Financial Officer at ZELTIQ Aesthetics, Inc., and held a number of operational and financial positions in strategic planning, global finance, IT and administration.
At ZELTIQ as Senior Managing Director of International Sales and Corporate Development, he led the launch of its first commercial product in all markets outside of the United States and Canada.
Prior to joining ZELTIQ, Mr. Brumm was Director of Finance at Proteolix, Inc., helping in the sale of the company to Onyx Pharmaceuticals. He has also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley.
Mr. Brumm was Founder and Chief Executive Officer of Nu-Ag Distribution, LLC, an agricultural consulting company.
He holds a BA in Business Administration from the University of Notre Dame.
Mr. Westberg has more than twenty years of transactions, operations, and advisory experience focused on advancing innovative technologies/products in the life sciences sector.
Mr. Westberg joined Versartis from Bayhill Therapeutics, where he was the Vice President of Business Development responsible for the company’s licensing activities and was a key contributor to its private equity fundraisings, IPO preparations and operational activities.
Prior to Bayhill, Mr. Westberg was the Vice President of Business Development at Novacea where he was responsible for multiple transactions including the in-licensing of two clinical stage oncology products.
Prior to Novacea, Mr. Westberg held managerial positions at Deltagen, Collabra Pharma, Aviron and positions of increasing responsibility at Genentech. He began his career advising clients on product and company valuation, technology assessment and commercialization issues.
Mr. Westberg holds an MBA from the Haas School of Business at the University of California, Berkeley and a BA in Applied Mathematics from the University of California, San Diego. ■